IMR Press / FBL / Volume 16 / Issue 4 / DOI: 10.2741/3799

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Contribution of PKB/AKT signaling to thyroid cancer
Show Less
1 Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, University Campus Germaneto, Catanzaro 88100, Italy
2 Institute for Genetic Research G. Salvatore, Ariano Irpino (AV), 83131 Italy
Front. Biosci. (Landmark Ed) 2011, 16(4), 1461–1487; https://doi.org/10.2741/3799
Published: 1 January 2011
Abstract

The family of serine/threonine kinases B/Akt (hereafter Akt) represents a central node in signalling pathways downstream of growth factors, cytokines, and other cellular stimuli. In mammalian cells the Akt family comprises three highly homologous members -known as Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma- that regulate several processes including cell proliferation and survival, growth and response to nutrient availability, migration, tissue invasion and angiogenesis. Aberrant activation of Akt is involved in a variety of human cancers including those arising in the thyroid gland. Here, we review the contribution of Akt-dependent pathway in the proliferation of normal thyrocytes, the different pathogenic mechanisms underlying aberrant Akt signalling in thyroid malignancies as well as the relative roles of Akt substrates that most likely contribute to the onset and/or progression of thyroid cancer. Finally, we discuss the current therapeutic strategies targeting the components of the PI3K/Akt pathway in the context of thyroid malignancy.

Share
Back to top